Promega corporation:1107424 - celltiter-fluor(TM) cell viability assay, 2 X 50ML and other reagents for NIH/ncats staff menghang XIA
Ended Awarded
- Contract number
- HHSN31900006
- Awardee
-
Promega Corporation UEI MWM4N9L4S5X4
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $24,520
Award facts
- Contract value 100% obligated
- $24,519.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Madison, WI 53711, USA
Award details come from SAM.gov/FPDS.
About this award
Promega Corporation was awarded a firm fixed-price BPA call valued at $24,519.90 by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health. The contract, awarded on September 25, 2015, with an ultimate completion date of February 29, 2016, procures CellTiter-Fluor cell viability assay reagents (2 x 50mL) and other associated reagents for use by NCATS staff member Menghang Xia. The work will be performed at Promega's Madison, Wisconsin location. This award does not utilize a small business set-aside designation, reflecting Promega's status as a large business capable of meeting federal research requirements.
This task order is issued under Promega's existing $10 million Blanket Purchase Agreement with the NIH's Office of Logistics and Acquisition Operations, which authorizes the procurement of biological materials, chemicals, medical and scientific equipment, and maintenance services across multiple NIH institutes and centers. The CellTiter-Fluor assay represents the type of specialized laboratory reagent that supports NCATS's translational research mission, enabling researchers to assess cell viability in drug screening and compound evaluation applications essential to advancing therapeutic development from laboratory discovery to clinical practice.
Quick answers
Who was awarded contract HHSN31900006?
HHSN31900006 was awarded to Promega Corporation by National Center for Advancing Translational Sciences (National Institutes of Health) on September 25, 2015.
How much is contract HHSN31900006 worth?
The government has obligated $24,520 on HHSN31900006.
Is contract HHSN31900006 an order under another contract?
Yes. HHSN31900006 is a BPA call under HHSN263201500038B, a blanket purchase agreement.
Was contract HHSN31900006 competed?
The extent of competition for HHSN31900006 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award